跳至主要内容
临床试验/NCT02614170
NCT02614170已完成不适用

A Prospective Collection of Peripheral Blood and Urine Specimens to Study C-peptide and Insulin in Healthy Individuals

Fujirebio Diagnostics, Inc.1 个研究点 分布在 1 个国家目标入组 328 人开始时间: 2015年3月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
328
试验地点
1
主要终点
Measure C-peptide and Insulin in Healthy Individuals

研究概览

简要总结

The study objectives are described below:

  1. Obtain matched serum, plasma [(K2 EDTA, Sodium Heparin (NaH), Lithium Heparin (LiH)] and urine specimens collected from a minimum of 50 healthy subjects. Specimens will be used to determine a reference range for C-peptide and insulin assays, used as an aid in the assessment of C-peptide and insulin in adults.
  2. Obtain serum and urine specimens collected from a minimum of an additional 200 healthy subjects. Specimens will be used to determine a reference range for C-peptide and insulin assays, used as an aid in the assessment of C-peptide and insulin in adults.
  3. To store any remaining specimens for use in future assay development and to evaluate as yet undetermined assays for the development of IVDs, including additional C-peptide or insulin assays.

详细描述

The primary object of this study is to obtain a series of blood and urine specimens from women and men who are healthy with no history of abnormal blood sugar levels. The specimens will be used to evaluate new C-peptide and insulin assays (tests). Participants are being asked to voluntarily take part in this study because they are a healthy individual without a history of abnormal blood sugar levels.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Males and females, age ≥ 18 years
  • Fasting for 12 hours prior to blood draw and random urine collection
  • Able to understand and willing to provide informed consent
  • Normal HbA1c (e.g. less than 5.7%) and glucose (e.g. less than 100 mg/dL) levels

排除标准

  • Males and females, age <18 years
  • Has a current diagnosis of any clinically significant cardiac, respiratory, neurological, immunological, hematological, liver disease, renal disease, gastrointestinal (GI) disorder, including any history of hyper- or hypothyroid, peptic or gastric ulcers or GI bleeding, or any other condition which, in the opinion of the investigator, would deem the subject unhealthy and therefore, ineligible.
  • Has a history of any clinically significant cardiac, respiratory, neurological, immunological, hematological, liver disease, renal disease, gastrointestinal (GI) disorder, including any history of hyper- or hypothyroid, peptic or gastric ulcers or GI bleeding, or any other condition which, in the opinion of the investigator, is unstable at the time of enrollment.
  • Current diagnosis or prior history of any type of diabetes including gestational diabetes.
  • Currently taking or history of insulin therapy for any disease.
  • Elevated HbA1c level (e.g. greater than 5.7%)
  • Elevated glucose level (e.g. greater than or equal to 100 mg/dL)
  • Is receiving systemic chemotherapy or radiation treatment, has an active malignancy of any type, or has been diagnosed with cancer within 5 years before screening other than basal or squamous cell skin cancers or in-situ cervical cancer.
  • History of seizures
  • Diagnosed with an infectious disease including any sexually transmitted diseases.
  • Diagnosed with HIV/AIDS or ever tested positive for HIV.
  • History of hepatitis
  • Subject that has had sexual contact with a person who has hepatitis within the last 12 months.
  • Pregnancy or lactation
  • Non-fasting for 12 hours prior to blood and random urine collection.
  • Hemolytic blood specimen
  • Unable to provide informed consent

结局指标

主要结局

Measure C-peptide and Insulin in Healthy Individuals

时间窗: 10 months

250 healthy subjects

次要结局

未报告次要终点

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验